Pfizer (NYSE:PFE)‘s stock had its “buy” rating reaffirmed by investment analysts at TheStreet in a note issued to investors on Monday, Stock Ratings Network reports.
The analysts wrote, “Pfizer (PFE) has been reiterated by TheStreet Ratings as a buy with a ratings score of A. The company’s strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”
Pfizer (NYSE:PFE) opened at 31.50 on Monday. Pfizer has a 52 week low of $24.63 and a 52 week high of $32.50. The stock has a 50-day moving average of $31.34 and a 200-day moving average of $29.32. The company has a market cap of $204.2 billion and a price-to-earnings ratio of 8.71. Pfizer also was the target of unusually large options trading activity on Friday. Investors bought 26,511 call options on the stock. This is an increase of approximately 158% compared to the average daily volume of 10,283 call options.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.58 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.56 by $0.02. The company had revenue of $12.64 billion for the quarter, compared to the consensus estimate of $12.69 billion. During the same quarter in the prior year, the company posted $0.53 earnings per share. The company’s quarterly revenue was down 2.4% on a year-over-year basis. Analysts expect that Pfizer will post $2.18 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on PFE. Analysts at Goldman Sachs Group Inc. downgraded shares of Pfizer from a “conviction-buy” rating to a “buy” rating in a research note to investors on Tuesday, December 3rd. Separately, analysts at Thomson Reuters/Verus upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note to investors on Monday, November 25th. Finally, analysts at Thomson Reuters/Verus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note to investors on Monday, November 11th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $31.77.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.